Murtuza Rampurwala to Receptor, ErbB-2
This is a "connection" page, showing publications Murtuza Rampurwala has written about Receptor, ErbB-2.
Connection Strength
0.647
-
Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer. PLoS One. 2019; 14(6):e0217778.
Score: 0.616
-
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res. 2016 06 01; 22(11):2659-67.
Score: 0.031